KRAS G12C — Targeted Therapies, Trials & Pipeline
The first directly druggable KRAS allele — covalent G12C inhibitors are approved in NSCLC and colorectal cancer.
The first directly druggable KRAS allele — covalent G12C inhibitors are approved in NSCLC and colorectal cancer.